Detailed Information on Publication Record
2021
In vivo Molecular Signatures of Cervical Spinal Cord Pathology in Degenerative Compression
HORÁK, Tomáš, Magda HORÁKOVÁ, Alena SVÁTKOVÁ, Zdeněk KADAŇKA, Petr KUDLIČKA et. al.Basic information
Original name
In vivo Molecular Signatures of Cervical Spinal Cord Pathology in Degenerative Compression
Authors
HORÁK, Tomáš (203 Czech Republic, belonging to the institution), Magda HORÁKOVÁ (203 Czech Republic, belonging to the institution), Alena SVÁTKOVÁ (703 Slovakia), Zdeněk KADAŇKA (203 Czech Republic, belonging to the institution), Petr KUDLIČKA (203 Czech Republic, belonging to the institution), Jan VALOSEK (203 Czech Republic), Tomáš ROHAN (203 Czech Republic), Miloš KEŘKOVSKÝ (203 Czech Republic), Eva VLČKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KADAŇKA (203 Czech Republic), Dinesh K. DEELCHAND, Pierre-Gilles HENRY, Josef BEDNAŘÍK (203 Czech Republic, belonging to the institution) and Petr BEDNAŘÍK (203 Czech Republic, guarantor, belonging to the institution)
Edition
Journal of Neurotrauma, New Rochelle, Mary Ann Liebert, 2021, 0897-7151
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30210 Clinical neurology
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.869
RIV identification code
RIV/00216224:14110/21:00120166
Organization unit
Faculty of Medicine
UT WoS
000745030000006
Keywords in English
cervical spinal cord; compression; degenerative magnetic resonance; myelopathy; spectroscopy
Tags
International impact, Reviewed
Změněno: 9/10/2024 13:35, Ing. Jana Kuchtová
Abstract
V originále
Degenerative cervical myelopathy (DCM) is a severe consequence of degenerative cervical spinal cord (CSC) compression. The non-myelopathic stage of compression (NMDC) is highly prevalent and often progresses to disabling DCM. This study aims to disclose markers of progressive neurochemical alterations in NMDC and DCM by utilizing an approach based on state-of-the-art proton magnetic resonance spectroscopy (1H-MRS). Proton-MRS data were prospectively acquired from 73 participants with CSC compression and 47 healthy controls (HCs). The MRS voxel was centered at the C2 level. Compression-affected participants were clinically categorized as NMDC and DCM, radiologically as mild (MC) or severe (SC) compression. CSC volumes and neurochemical concentrations were compared between cohorts (HC vs. NMDC vs. DCM and HC vs. MC vs. SC) with general linear models adjusted for age and height (pFWE < 0.05) and correlated to stenosis severity, electrophysiology, and myelopathy symptoms (p < 0.05). Whereas the ratio of total creatine (tCr) to total N-acetylaspartate (tNAA) increased in NMDC (+11%) and in DCM (+26%) and SC (+21%), myo-inositol/tNAA, glutamate + glutamine/tNAA, and volumes changed only in DCM (+20%, +73%, and −14%) and SC (+12%, +46%, and −8%, respectively) relative to HCs. Both tCr/tNAA and myo-inositol/tNAA correlated with compression severity and volume (−0.376 < r < −0.259). Myo-inositol/tNAA correlated with myelopathy symptoms (r = −0.670), whereas CSC volume did not. Short-echo 1H-MRS provided neurochemical signatures of CSC impairment that reflected compression severity and clinical significance. Whereas volumetry only reflected clinically manifest myelopathy (DCM), MRS detected neurochemical changes already before the onset of myelopathy symptoms.
Links
NV18-04-00159, research and development project |
| ||
90042, large research infrastructures |
| ||
90129, large research infrastructures |
|